首页> 外文期刊>Scientific reports. >Functional capillary impairment in patients with ventricular assist devices
【24h】

Functional capillary impairment in patients with ventricular assist devices

机译:心室辅助装置患者的功能性毛细血管损伤

获取原文
           

摘要

The implantation of continuous - flow ventricular assist devices (VAD) is suggested to evoke angiodysplasia contributing to adverse events such as gastrointestinal bleeding. We evaluated in vivo capillary density and glycocalyx dimensions to investigate possible systemic microvascular changes in patients with chronic heart failure and VAD support vs. standard medical treatment. Forty-two patients with VAD support were compared to forty-one patients with ischemic and non-ischemic chronic heart failure (CHF) on standard pharmacotherapy and to a group of forty-two healthy subjects in a prospective cross-sectional study. Sublingual microcirculation was visualized using Sidestream Darkfield videomicroscopy and functional and perfused total capillary densities were quantified. Patients with VAD implantation were followed for one year and bleeding events were recorded. Median time after VAD implantation was 18 months. Patients were treated with centrifugal-flow devices (n?=?31) or axial-flow devices (n?=?11). Median functional capillary density was significantly lower in patients with VAD therapy as compared to CHF patients (196 vs. 255/mmsup2/sup, p?=?0.042, adjusted p-value). Functional and total capillary densities were 44% and 53% lower (both p??0.001) in patients with VAD therapy when compared to healthy subjects. Cox regression analysis revealed loss of capillary density as a significant predictor of bleeding events during one -year follow-up of VAD patients (HR: 0.987, CI (95%): 0.977-0.998, p?=?0.021 for functional and 0.992, CI (95%): 0.985-0.999, p?=?0.03 for total capillary density). In conclusion, patients with VAD support exhibit capillary density rarefaction, which was associated with bleeding events. If confirmed independently, capillary impairment may be evaluated as novel marker of bleeding risk.
机译:建议植入连续流式心室辅助设备(VAD)引起血管增生,增生不良反应如胃肠道出血。我们评估了体内毛细血管密度和糖萼尺寸,以调查慢性心力衰竭和VAD支持与标准药物治疗患者相比,可能的全身微血管变化。在一项前瞻性横断面研究中,将42例接受VAD支持的患者与41例接受标准药物疗法治疗的缺血性和非缺血性慢性心力衰竭(CHF)患者以及42例健康受试者进行了比较。使用Sidestream Darkfield视频显微镜观察舌下微循环,并对功能性和灌注总毛细血管密度进行定量。 VAD植入患者随访一年,并记录出血事件。 VAD植入后的中位时间为18个月。用离心流动装置(n?=?31)或轴流装置(n?=?11)治疗患者。与CHF患者相比,VAD治疗患者的功能性毛细血管中位数明显降低(196 vs. 255 / mm 2 ,p?=?0.042,调整后的p值)。与健康受试者相比,接受VAD治疗的患者的功能性毛细血管密度和总毛细血管密度分别降低了44%和53%(均p 0.001)。 Cox回归分析显示,在VAD患者的一年随访期间,毛细血管密度的丧失是出血事件的重要预测指标(HR:0.987,CI(95%):0.977-0.998,功能性p?=?0.021,0.992, CI(95%):0.985-0.999,对于总毛细管密度,p≥= 0.03。总之,有VAD支持的患者表现出毛细血管密度稀疏,这与出血事件有关。如果独立确认,毛细血管损伤可作为出血风险的新标志。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号